Rigel Pharmaceuticals (RIGL) Capital Expenditures Growth (3y) (2013 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 46.88% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.97% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 16.27% |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -29.35% |
| Dec 31, 2024 | 47.94% |
| Dec 31, 2022 | -50.75% |
| Sep 30, 2022 | -18.72% |
| Jun 30, 2022 | -32.25% |
| Mar 31, 2022 | -15.93% |
| Dec 31, 2021 | -32.08% |
| Sep 30, 2021 | 2.91% |
| Jun 30, 2021 | -15.89% |
| Mar 31, 2021 | -28.84% |
| Dec 31, 2020 | 111.86% |
| Sep 30, 2020 | 51.57% |
| Jun 30, 2020 | -72.61% |
| Mar 31, 2020 | 145.55% |
| Dec 31, 2019 | 366.98% |
| Sep 30, 2019 | 11.78% |
| Jun 30, 2019 | -20.05% |
| Mar 31, 2019 | 5.51% |
| Dec 31, 2018 | -19.85% |
| Sep 30, 2018 | -20.20% |
| Jun 30, 2018 | 110.82% |
| Mar 31, 2018 | 83.28% |
| Dec 31, 2017 | -35.77% |
| Sep 30, 2017 | 50.37% |
| Jun 30, 2017 | -42.85% |
| Mar 31, 2017 | -38.70% |
| Dec 31, 2016 | -67.07% |
| Sep 30, 2016 | 25.33% |
| Jun 30, 2016 | -3.32% |
| Mar 31, 2016 | -21.98% |
| Dec 31, 2015 | -39.36% |
| Sep 30, 2015 | -7.19% |
| Jun 30, 2015 | -55.31% |
| Mar 31, 2015 | -72.71% |
| Dec 31, 2014 | 2.63% |
| Sep 30, 2014 | -27.47% |
| Jun 30, 2014 | -52.44% |
| Mar 31, 2014 | -40.85% |
| Dec 31, 2013 | -43.43% |
| Sep 30, 2013 | -47.74% |